TRex Bio (TRXB) files S-1 for Nasdaq IPO in the 2026 listing surge
As seen on the 24/7 Wall St. homepage on September 18, 2026.
TRex Bio files for Nasdaq IPO with five banks behind it
TRex Bio filed its S-1 to list on Nasdaq with a five-bank syndicate behind it. Terms are not set yet, so the price range in the next amendment is the number that decides whether this Treg-focused biotech gets priced into the record 2026 listing run.
Continue ReadingShow less
TRex Bio, Inc. submitted its S-1 registration statement to the SEC on September 18, 2026, formally kicking off the process to list on Nasdaq. The filing puts this Treg-focused biotech into the queue for what has been a record year for new listings.
Five underwriting banks have signed on to the deal, a syndicate size that signals meaningful institutional backing at the earliest stage of the process. That kind of lineup typically helps a company build a broad order book when the roadshow begins.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
No price range, share count, or deal size has been set yet. Those terms will appear in an amended S-1, and the price range disclosed in that amendment is the figure that will tell investors how the banks and the company are valuing the business heading into pricing.
For investors tracking the IPO market, the next amendment is the material event to watch. A strong price range relative to peers in the regulatory T-cell therapy space would confirm that demand from institutional accounts is holding up in the 2026 listing environment.